Showing posts with label Cancer. Show all posts
Showing posts with label Cancer. Show all posts

Monday, November 23, 2009

Healthcare: Is cost control possible?

Teenagers love to spend, Health care consumers love to test.

Recent mammogram debate shows why reform will fail - most women don't like to get mammograms later in life and less frequently. Of course, this furious reaction is fueled by those who would face payment cuts if the new guidelines are implemented - radiologists, for example.

How many medical tests do you need to sleep sound at night knowing that you are healthy enough? Billions, trillions, googols?
How many out of a few thousand existing medical tests are redundant or irrelevant to individual consumers?

Mamograms and colonoscopies are perfect examples of overused diagnostic procedures. (see also the consumerreports article on overused tests and treatments).

Colonoscopy accounts for up to 75% of costs of an IBS patient, while the probability of it yielding meaningful results is less than 3%.
Citing Dr. Rex: Low-risk patients might undergo too many colonoscopies; high-risk patients, too few. When given a range of hypothetical findings on initial colonoscopy, most physicians would recommend repeat colonoscopy earlier than is indicated by the U.S. Multi-Society Task Force guidelines.

If 2000 women are screened regularly for 10 years, one will benefit from the screening, as she will avoid dying from breast cancer.10 healthy women, however, will have either a part of their breast or the whole breast removed. Even statistics deny that early screening for breast cancer saves lives.

Early and frequent screenings often lead to false alarms and unneeded biopsies, without substantially improving women's odds of survival. About 90 percent of abnormal mammogram findings are benign. A 2009 study in the British Medical Journal estimated that roughly one in three breast cancers detected by mammograms would never have caused harm. Earlier studies were suggesting this too, raising (along with harmful consequences of false positive results)

Perhaps the biggest problem with performing too many screening tests in healthy people is a phenomenon called over-diagnosis: Screening can detect slow-growing, harmless cancers that would never have killed you. But even if a mammogram "involves a tiny dose of radiation", a bigger dose used in radiotherapy is harmful when given to healthy people. Breast cancer radiotherapy regimens can increase mortality from heart disease and lung cancer 10-20 years afterwards.

How often does this happen with breast cancer?

Dr. Kevin Pho, an internist in Nashua, N.H., thinks the rebellion indicates a larger problem with ObamaCare. "The fact that [the administration] is distancing itself from what I consider to be very robust guidelines portends a very poor future for comparative effectiveness," he says. "If they back down now, what's going to happen when a comparative effectiveness body says there's no difference between angioplasty and medical management of heart disease?"

The American College of Obstetrics and Gynecology (ACOG) has just revised their guidelines for Pap smears under some pressure. This resulted from an Annals of Internal Medicine article which documented that only 16.4% of gynecologists followed the College’s prior guidelines. Most did more screenings than indicated, the worst record of the specialties tested. But the ACOG still recommends that nearly all women obtain regular screening at intervals of 1-3 years.

Cervical cancer is a rare disease in the US: just over 11,000 cases are predicted in 2009. There will be nearly as many cases of testicular cancer, 8,400. In comparison both breast and prostate cancer are just under 200,000. Most women have been led to believe that cervical cancer is rampant and they need yearly screening to prevent it. Testicular cancer however, is rarely mentioned. Most physicians don’t even bother to recommend that young men self-examine.

Here is a different example. Man sues over “botched” testicular surgery. Doctors later discovered that the tumor was not malignant and did not need to be removed. Was it possible to offer a better testing, say biopsy? Urologists can tell you that testes should never be biopsied prior to removal if cancer is suspected as it significantly increases the risk of tumor dissemination. Studies show that those who had scrotal incisions for biopsy have a higher local recurrence rate as well as a higher relapse rate. If there is a solid growth in the testes, there is 95-97% probability of the growth being malignant. Sounds very reasonable, in this case doctors are sued for proper care, but was another cost - the cost of inconvenience, perhaps even mental trauma - ever taken into consideration?

Medicine is as much art as science – there are many cases where there are no “right” answers. Health care providers can prescribe as many procedures as they want and charge whatever they like. It's time for this to be changed.

Personal risk of cervical cancer, for example, can be easily estimated by every woman as it depends on whether she had multiple sexual partners, prior negative Paps, long term mutually monogamous relationship. HIV (that has a five times greater incidence than cervical cancer) tests are not administered to people without risks, right? Well, not quite right, but that's another story.

Dr. Joel Sherman (Medical Privacy, A Patient Oriented Discussion) has seen many women who are angry that the facts on cervical cancer have been hidden from them. They are pushed into getting Paps, but never told the pros and cons of screening. Never mentioned are the high incidence of abnormalities that resolve spontaneously, like negative biopsies and colposcopies.

And last, but not least - another reason of why healthcare is so costly - the insurer's overestimates, in a way their overdiagnosis of our health problems.

If the law says insurers have to treat every person the same, without taking into account whether they’re sick or healthy, young or old, a rational insurer will do some rational things. For example, it will assume disproportionate numbers of people who buy a policy from them will be sick and old. Of course, when they do this, the product becomes expensive, and young, healthy people start to wonder if they should even buy it in the first place. After all, they don’t really need insurance, right? Coupled with the overall rise in the cost of health care, insurers now push through new rounds of price increases, which, in turn, create more uninsured people. It is a very nasty cycle.

Aurametrix is developing decision support systems to help you evaluate personal health risks, decide on preventative measures, estimate cost/benefits of performing diagnostic tests. Better tools for a healthier world.


Reblog this post [with Zemanta]

Wednesday, November 4, 2009

Thoughts on the Future of Dx



Workflow, procedures and organization of diagnostic laboratories have changed little since the end of the 19th century. Technology improved quality and safety, lead to higher throughput and allowed private electronic access to patients' lab test results - at least partially, but other than that not much has changed.

The introduction of first generation transcriptome technologies in the mid 1990s (Schena et al., 1995; DeRisi et al., 1996) has led to a phenomenal ability to simultaneously measure thousands of genes, create molecular profiles of cancers, all other diseases and conditions.

Proteomics - coined a couple of years later (James, 1997) - was accepted as an even more promising technique for effective diagnostics of diseases. Figure on the left, however, demonstrates that it too faces many challenges from discovery of biomarkers to their verification and approval. After more than a decade (Oliver et al., 1998), metabolomics has been accepted as - at least - an equally promising technique, but it still lagging behin genomics and proteomics.

All these techniques will have significant impact on the business model of diagnostics. Multiplexing (measuring multiple biomarkers at once) is obviously much more cost-effective. Diagnostics industry is historically very resistant to disruptive technological change, but potential cost advantages should outweigh this, leading to novel business models in health management.

A change will also come from the growing near patient testing (NPT) sector. NPT is already finding a role in wellness monitoring. Existing self tests - such as cholesterol kits - may not be very accurate, but with the advent of inexpensive multiplexing assays this will be overcome. Even when blood testing is done by trained professionals in a lab, there can be significant variability in test results. Same applies to blood pressure measurements - you may need to do three measurements per day for five days in order to get a decent baseline. This only justifies the need to have inexpensive tests that can be done more often.

But lets go back to metabolomics and its potential to provide noninvasive inexpensive diagnostics. Are there any clinical trials attempting to translate it into clinical practice?
Here are our favorite ones:

CANCER
NCT00757952: Diagnosing ovarian cancer in exhaled breath. (Pine Street Foundation & University of Maine)
NCT00898209: Diagnosing Lung cancer in exhaled breath. (Vanderbilt-Ingram Cancer Center)
NCT00898209: Exhaled breath analyzed for lung cancer. (Vanderbilt-Ingram Cancer Center)
NCT00639067: Breath test for early detection of lung cancer (Menssana Research)
NCT00873366: Breath tests to access effectiveness of breast cancer treatment (Mayo Clinic and National Cancer Institute (NCI))

OTHER
NCT00330603: Metabolomic breath analysis to predict treatment for chronic cough (University of Virginia)
NCT00632307: Breath analysis to diagnose COPD; lung cancer; airway infection; interstitial lung disease, sleep apnea; pulmonary disorders with pleural infusions; sarcoidosis (Lung Clinic Hemer, Germany)
NCT00294489: Breath analysis to diagnose Hepatitis C (Hadassah Medical Organization, Jerusalem, Israel)


References
Schena M, Shalon D, Davis RW, Brown PO 1995 Quantitative monitoring of gene expression patterns with complementary DNA microarray. Science 270 : 467 –470[Abstract/Free Full Text]

DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA
1996 Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 14 : 457 –460[CrossRef][Medline]

James P 1997 Protein identification in the post-genome era: the rapid rise of proteomics.". Quarterly reviews of biophysics 30 (4): 279–331. doi:10.1017/S0033583597003399. PMID 9634650.

Oliver SG, Winson MK, Kell DB, Baganz F. 1998. Systematic functional analysis of the yeast genome. Trends in Biotechnology 16: 373-378.

Aurametrix is conducting research to develop next-generation diagnostics to help you evaluate your personal health risks and benefits. Better tools for a healthier world.
Reblog this post [with Zemanta]

Friday, August 28, 2009

Metabonomic Profiling as a Non-invasive Inexpensive Diagnostics Tool

Small molecules in our breath, saliva, sweat and other body fluids can tell a lot about our health and disease, state of mind, therapeutic outcomes, athletic and mental performance, tapping into both genetic and environmental factors influencing our lives.

Urinary metabonomic profiling, for example, predicts metabolism of drugs and xenobiotics, as was recently shown by Imperial College London and Pfizer teams. Relative concentrations of small molecules such as p-cresol sulfate could be used for prediction of drug treatment outcomes. Qulitative measurements of lipids, metabolites, proteins and complexes predict sensitivity to biologics such as anti-HER2 therapy. (see full article in pdf)

Many existing and emerging diagnostics tools used as the gold standard for diagnosis of cancers are expensive and invasive. Metabolic profiling would solve the cost issue and would not require penetration, catheterization, incision nor breaking the skin and into body cavities. Recent study demonstrates potential of metabonomics in diagnostics of bladder cancers. This is not surprising, as well-trained dogs can fairly accurately identify patients with bladder cancer based on urine odor.They do well identifying lung and breast cancers, ovarian carcinomas, endometrial cancer, renal cell carcinoma, epileptic and psychogenic non-epileptic seizures and many other conditions too, all based on unique signatures of metabolites in human odors.

Metabolic profiling of plasma showed potential for diagnostics of Parkinson's disease through its early symptomatic phase. As seen in the figure, concentration of many molecules was significantly different, but pyruvate was the key metabolite. Sarcosine, an N-methyl derivative of the amino acid glycine, was identified as a differential metabolite during prostate cancer progression to metastasis.

Metabolite profiling was shown to be a promising diagnostic technique for coronary heart disease, diabetes mellitus, pediatric clinical studies, eclampsia, lipid disorder , skin cancer, colon carcinoma, metastatic prostate cancer, epithelial ovarian cancer , liver cancer, lung cancer, hypertension , kidney deficiency syndrome, infertility treatment, and motor neuron disease. Devices checking for metabolites in the air can tell the difference between Coke and Pepsi, healthy and sick trees and people. Besides traditional mass spec and GC analyzers, many nanotechnology-based device prototypes are being built, such as gold nanoparticle based, colorimetric arrays, or xerogel sensor with CMOS detector. New findings are announced every month.

Metabolic profiling distinguish people with 99% accuracy, even healthy monozygotic twins have different profiles, demonstrating yet again that metabolites are products of gene-environment interaction, bearing more information about us than just genes.

Aurametrix is conducting research to develop next-generation mobile devices to help you evaluate your personal health risks and benefits. Better tools for a healthier world.

Reblog this post [with Zemanta]

Tuesday, June 2, 2009

Can dogs detect cancer? Invitation to event



Can Dogs Detect Cancer?

A movie, demo, and discussion about dog scent detection and ovarian cancer

Wednesday June 10th 6-7 pmdogs sniffing cancer
LGBT Center, 1800 Market St @ Octavia
San Francisco, CA
Cost: FREE
Free childcare available during the event
by RSVP to (415) 342-0886

Come hear about groundbreaking, federally funded, ovarian cancer research being conducted in the bay area and learn more about the symptoms and risks of ovarian cancer.

A documentary will be shown and there will be Q&A with Pine Street Foundation’s Principal Investigator, Michael McCulloch, LAc, MPH, PhD.
Watch a live demo and meet “Tessy”, the dog featured in this month’s Oprah Magazine article, “Sniffing Out Cancer”.

Representatives from the San Francisco chapter of The National Ovarian Cancer Coalition will be available for information and questions.

Women who are interested in donating a breath sample at the event may call (415) 342-0886 by Friday June 5th. Breath samples are sought from non-smoking women, 21+, who have been recently diagnosed with ovarian cancer, polycystic ovarian syndrome (PCOS), or endometriosis.

SPONSORED BY
PINE STREET FOUNDATION
NATIONAL OVARIAN CANCER COALITION (SF CHAPTER)

Frequently Asked Questions
Can dogs really detect cancer? How did you collect breath samples? Click here for answers to these questions and more.

Canine Scent Detection of Ovarian Cancer
This study is currently in progress. Click here for the latest on this study as well as how you can participate.

Canine Scent Detection of Lung and Breast Cancer
This ground-breaking study was published in 2006. Click here for more information about this research as well as the full paper.

Aurametrix is an early phase company working on Health 4.0 technologies
Reblog this post [with Zemanta]
blockquote { margin:1em 20px; background: #dfdfdf; padding: 8px 8px 8px 8px; font-style: italic; }